ANGLE Company Description

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally.

The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis.

It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal transition; and CellKeep Slide, a CTC harvesting technology.

In addition, the company offers laboratory services, including enumeration of epithelial and mesenchymal CTC populations; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays.

ANGLE plc has a strategic partnership with Bio View Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use its proprietary pan-cancer next generation sequencing (NGS) panel.

The company was founded in 1994 and is based in Guildford, the United Kingdom.

ANGLE plc

Country	United Kingdom
Founded	1994
Industry	Medical - Diagnostics & Research
Sector	Healthcare
Employees	150
CEO	Andrew David Newland

Contact Details

Address: Surrey Research Park Guildford, GU2 7AF United Kingdom
Phone	44 14 8334 3434
Website	angleplc.com

Stock Details

Ticker Symbol	AGL
Exchange	London Stock Exchange AIM
Fiscal Year	January - December
Reporting Currency	GBP
ISIN Number	GB0034330679
SIC Code	3845

Key Executives

Name	Position
Andrew David Newland	Chief Executive Officer
Ian Griffiths	Chief Financial Officer
Martin Cooke	Chief Operating Officer
Andrew Holder	Head of Investor Relations